deprotonation of the Michael acceptor and to give im-
proved yields and diastereoselectivities (Scheme 1, eq 1).
Therefore, we envisioned that more nucleophilic metallo-
enamines derived from N-sulfinyl imidates and more
electrophilic R,β-unsaturated diesters derived from diethyl
arylidenemalonates would more effectively facilitate the
Michael addition reaction (Scheme 1, eq 2).
2-(3-((R)-tert-butylsulfinylimino)-3-methoxy-1-arylpropyl)-
malonates. The application of this chemistry was further
demonstrated through the efficient synthesis of 3-substi-
tuted 1-indanone derivatives with high enantiomeric ex-
cess, which are potential building blocks of biologically
active lead compounds.
Table 1. Optimization of the Reaction Conditions of Synthesis
of 3aa
Scheme 1. Michael Additions to R,β-Unsaturated Compounds
entry
base (equiv)
time (h)
yield (%)
dr
1b
2c
3d
4
NaHMDS (1.5)
KHMDS (1.5)
LiHMDS (1.5)
LDA (1.5)
2
2
95
93
94
90
90
73
89
87
85
85
94
84
85:15
87:13
90:10
93:7
95:5
96:4
88:12
96:4
95:5
96:4
98:2
97:3
2
2
5
LDA (1.2)
2
6
LDA (1.0)
2
Successful Michael additions to R,β-unsaturated dies-
ters 2 would be of particular interest because the addition
products 3 could potentially be converted to chiral 3-sub-
stituted-1-indanones 8 by simple deprotection, decarbox-
ylation, and cyclization reactions (Scheme 4). Substituted
indanone rings are well-known privileged structures which
are widely distributed in natural products and biologically
synthetic compounds.8 They exhibit a wide spectrum of
biological activities, such as smooth muscle relaxant, anti-
cancer, anti-inflammatory activity, and acetylcholinesterase
(AChE) inhibition.9 Although some advances have been
achieved for the asymmetric synthesis of 3-substituted-1-
indanones, most of them suffered from the use of precious
metal catalysts and unreadily available ligands.10
In our ongoing efforts to develop efficient methods
to construct potential bioactive chiral heterocyclic
compounds,11 we herein describe an additive-free
and highly diastereoselective Michael addition reac-
tion of N-tert-butanesulfinyl imidate to diethyl aryl-
idenemalonates using LDA as a base to generate diethyl
7
LDA (1.8)
2
8
LDA (1.2)
5
9
LDA (1.2)
12
2
10e
11f
12g
LDA (1.2)
LDA (1.2)
2
LDA (1.2)
2
a Unless otherwise stated, all reactions were carried out using 1
(1.0 equiv, 0.2 mmol), 2a (1.5 equiv, 0.3 mmol), and 0.5 mol/L of LDA
as base at À78 °C in 5 mL of THF. b 1.0 mol/L of NaHMDS was used as
base. c 1.0 mol/L of KHMDS was used as base. d 1.0 mol/L of LiHMDS
was used as base. e 10 mL of THF was used as solvent. f 0.5 mol/L of LDA
was diluted to 0.25 mol/L. g 1.1 equiv of 2a was used.
N-tert-Butanesulfinyl imidate 1 and 2a were chosen as
model substrates for exploring the optimum reaction con-
ditions for the synthesis of optically pure diethyl 2-(3-((R)-
tert-butylsulfinylimino)-3-methoxy-1-arylpropyl)malonate
(3a) via asymmetric Michael addition (Table 1). First,
N-tert-butanesulfinyl imidate 1 was synthesized through
condensation of (R)-tert-butanesulfinamide with the cor-
responding ortho ester in the presence of a catalytic
amount of p-TsOH without solvent.5c Subsequently, the
Michael addition reaction of 1 and 2a was systematically
optimized by changing the reaction conditions (Table 1).
Commercially available NaHMDS was initially used as
the base, and full conversion of 1 was observed after 2 h
at À78 °C (95%) (Table 1, entry 1). However, the diaste-
reoselectivity (dr = 85:15) was not satisfactory. Replace-
ment of NaHMDS with KHMDS also resulted in a
disappointing diastereoselectivity (Table 1, entry 2). How-
ever, using LiHMDS as base gave an improved diastereo-
selectivity (dr = 90:10) (Table 1, entry 3). To further in-
crease the diastereoselectivity, 0.5 mol/L of LDA in THF
was freshly prepared. To our delight, the use of LDA
greatly improved the diastereoselectivity (Table 1, entries
4À12). When 1.5 equiv of LDA was used, 3a was obtained
(8) (a) Satake, T.; Murakami, T.; Yokote, N.; Saiki, Y.; Chen, C. M.
Chem. Pharm. Bull. 1985, 33, 4175. (b) Saito, M.; Umeda, M.; Enomoto,
M.; Hatanaka, Y.; Natori, S. Experientia 1975, 31, 829.
(9) (a) Sheridan, H.; Frankish, N.; Farrell, R. Eur. J. Med. Chem.
1999, 34, 953. (b) Nagle, D. G.; Zhou, Y. D.; Park, P. U.; Paul, V. J.;
Rajbhandari, I.; Duncan, C. J. G.; Pasco, D. S. J. Nat. Prod. 2000, 63,
1431. (c) Tumiatti, V.; Vincenza, A.; Banzi, R.; Bartolini, M.; Minarini,
A.; Rosini, M.; Melchiorre, C. J. Med. Chem. 2004, 47, 6490. (d)
Ssaravanan, V. S.; Selvan, P. S.; Gopal, N.; Gupat, J. K. Asian J. Chem.
2006, 18, 2597.
(10) (a) Shintani, R.; Takatsu, K.; Hayashi, T. Angew. Chem., Int. Ed.
2007, 46, 3735. (b) Shintani, R.; Yashio, K.; Nakamura, T.; Okamoto,
K.; Shimada, T.; Hayashi, T. J. Am. Chem. Soc. 2006, 128, 2772. (c) Arp,
F. O.; Fu, G. C. J. Am. Chem. Soc. 2005, 127, 10482. (d) Kundu, K.;
McCullagh, J. V.; Morehead, A. T., Jr. J. Am. Chem. Soc. 2005, 127,
16042. (e) Matsuda, T.; Shigeno, M.; Makino, M.; Murakami, M. Org.
Lett. 2006, 8, 3379.
(11) Chen, X. J.; Zhu, W.; Qian, W. K.; Feng, E. G.; Zhou, Y.; Wang,
J. F.; Jiang, H. L.; Yao, Z. J.; Liu, H. Adv. Synth. Catal. 2012, 354, 2151.
B
Org. Lett., Vol. XX, No. XX, XXXX